Table 1 PSQI total and individual scores throughout the study period
From: Trazodone for the treatment of fibromyalgia: an open-label, 12-week study
baseline | week 6 | week 12 | P (anova) | |
|---|---|---|---|---|
Total score (mean ± s.d.) | 16.2 ± 3.3 | 12.9 ± 4.1*** | 12.1 ± 5.0*** | < 0.0001 |
ES | 1.00 | 1.24 | ||
Sleep quality (mean ± s.d.) | 3.58 ± 0.5 | 1.78 ± 0.9*** | 1.64 ± 0.9*** | < 0.0001 |
ES | 3.6 | 3.88 | ||
Sleep latency (mean ± s.d.) | 2.49 ± 0.8 | 2.2 ± 0.9** | 1.9 ± 1.1*** | < 0.0001 |
ES | 0.36 | 0.73 | ||
Sleep duration (mean ± s.d.) | 2.58 ± 0.6 | 1.98 ± 1.0*** | 1.75 ± 1.1*** | < 0.0001 |
ES | 1.00 | 1.38 | ||
Sleep efficiency (mean ± s.d.) | 2.68 ± 0.7 | 2.03 ± 1.2*** | 1.59 ± 2.2*** | < 0.0001 |
ES | 0.93 | 1.56 | ||
Sleep disturbance (mean ± s.d.) | 2.36 ± 0.5 | 2.07 ± 0.6** | 2.02 ± 0.7*** | = 0.0001 |
ES | 0.58 | 0.68 | ||
Sleeping medications (mean ± s.d.) | 1.42 ± 1.5 | 0.97 ± 1.4* | 0.73 ± 1.2** | = 0.0033 |
ES | 0.30 | 0.46 | ||
Daytime dysfunction (mean ± s.d.) | 2.32 ± 0.8 | 2.02 ± 0.9** | 1.98 ± 0.9** | = 0.0013 |
ES | 0.38 | 0.42 |